Riskpilot← Back to searchSign inGet full accessAkiram Therapeutics AB
ABActiveOrg 5593387458Ihres Väg 38Manufacture of pharmaceutical preparations · NACE 2120Est. 20211 employees
Revenue 2024
SEK 29K
EBITDA margin
-28800.0%
+76% vs 2023
Equity ratio
93.8%
Financial strength
Net profit 2024
SEK -8M
+76% vs 2023
| Revenue | SEK 29K | — |
| EBITDA | SEK -8,4M | +76% |
| Net profit | SEK -8M | +76% |
| Total assets | SEK 24M | -44% |
| Equity | SEK 22,5M | -26% |
| Employees | 1 | — |
Legal name
Akiram Therapeutics AB
Org number
5593387458
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
6 oktober 2021
Share capital
SEK 55 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva forskning och utveckling av radiofarmaceutiska antikroppsläkemedel inom onkologi.
Address
Ihres Väg 38
Email
marikanestor@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 0 | 0 | 29 |
| Staff expenses | — | — | — |
| EBITDA | −7 029 | −34 191 | −8 352 |
| Depreciation & amort. | −0 | −0 | −0 |
| EBIT | −7 029 | −34 191 | −8 352 |
| Net financials | — | 599 | 387 |
| Profit before tax | −7 029 | −33 592 | −7 966 |
| Tax | −0 | −0 | −0 |
| Net profit | −7 029 | −33 592 | −7 966 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 10 810 | 43 000 | 23 982 |
| Equity | 3 746 | 30 464 | 22 498 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 7 064 | 12 535 | 1 483 |
| Total debt | 7 064 | 12 535 | 1 483 |
EBITDA margin
-28800.0%
This company
15.8%
Market median
-182378% vs market
20222024
Equity ratio
93.8%
This company
38.2%
Market median
+146% vs market
20222024
Return on equity
-35.4%
This company
18.4%
Market median
-292% vs market
20222024
Net profit margin
-27469.0%
This company
8.1%
Market median
-339223% vs market
20222024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222024
Debt / equity
0.07×
This company
0.62×
Market median
+89% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
SC Chief Auditor | Chief Auditor | 2022 |
MV Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2024 | |
| Board of Directors | 2024 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Akiram Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sofia Charlotta Tedstedt | Chief Auditor | 0 companies |
| Marika Viktoria Nestor | Chief Executive Officer | 0 companies |
| Anja Charlotte Lundgren Mortensen | Board of Directors | 0 companies |
| Anna Catarina Törner | Board of Directors | 0 companies |
| Peder Sven Walberg | Board of Directors | 0 companies |
| Sven Fredrik Yngve Frejd | Board of Directors | 0 companies |